



# See Our Sessions at the 2024 ASCO Annual Meeting

Published: May 2024

Session Name	START Principal Investigator
<a href="#"><u>Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors.</u></a>	Dr. Amita Patnaik
<a href="#"><u>A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.</u></a>	Dr. Amita Patnaik
<a href="#"><u>An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).</u></a>	Dr. Amita Patnaik
<a href="#"><u>TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.</u></a>	Dr. Amita Patnaik
<a href="#"><u>Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).</u></a>	Dr. Amita Patnaik



Session Name	START Principal Investigator
<a href="#"><u>First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.</u></a>	Dr. Amita Patnaik
<a href="#"><u>Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors.</u></a>	Dr. Drew Rasco
<a href="#"><u>Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.</u></a>	Dr. Drew Rasco
<a href="#"><u>Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.</u></a>	Dr. Drew Rasco
<a href="#"><u>Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors.</u></a>	Dr. Drew Rasco
<a href="#"><u>A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.</u></a>	Dr. Drew Rasco
<a href="#"><u>Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.</u></a>	Dr. Drew Rasco
<a href="#"><u>Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.</u></a>	Dr. Drew Rasco
<a href="#"><u>CIn-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.</u></a>	Dr. Drew Rasco



Session Name	START Principal Investigator
<a href="#"><u>Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.</u></a>	Dr. Kyriakos Papadopoulos
<a href="#"><u>A first-in-human, phase 1/2 trial of FOG-001, a <math>\beta</math>-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.</u></a>	Dr. Kyriakos Papadopoulos
<a href="#"><u>Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).</u></a>	Dr. Kyriakos Papadopoulos
<a href="#"><u>Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies.</u></a>	Dr. Kyriakos Papadopoulos
<a href="#"><u>Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors.</u></a>	Dr. Kyriakos Papadopoulos
<a href="#"><u>Phase 1 LITESPARK-001 study of belzutifan in advanced solid tumors: Results of the glioblastoma cohort.</u></a>	Dr. Kyriakos Papadopoulos
<a href="#"><u>Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.</u></a>	Dr. Kyriakos Papadopoulos
<a href="#"><u>A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC.</u></a>	Dr. Kyriakos Papadopoulos
<a href="#"><u>Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.</u></a>	Dr. Muralidhar Beeram



Session Name	START Principal Investigator
<a href="#"><u>Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.</u></a>	Dr. Manish Sharma
<a href="#"><u>First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.</u></a>	Dr. Manish Sharma
<a href="#"><u>Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC).</u></a>	Dr. Manish Sharma
<a href="#"><u>Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.</u></a>	Dr. Manish Sharma
<a href="#"><u>Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.</u></a>	Dr. Manish Sharma
<a href="#"><u>Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.</u></a>	Dr. Manish Sharma
<a href="#"><u>First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2– mBC.</u></a>	Dr. Manish Sharma
<a href="#"><u>Dose optimization and exposure-response analyses to support optimal dose of ABBV-400, a novel C-met–targeting antibody drug conjugate, in patients with metastatic colorectal cancer (mCRC).</u></a>	Dr. Manish Sharma
<a href="#"><u>Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met–targeting antibody-drug conjugate, in select advanced solid tumor indications.</u></a>	Dr. Manish Sharma



Session Name	START Principal Investigator
<a href="#"><u>First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.</u></a>	Dr. Sreenivasa Chandana
<a href="#"><u>DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.</u></a>	Dr. Sreenivasa Chandana
<a href="#"><u>A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors.</u></a>	Dr. Nehal Lakhani
<a href="#"><u>A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.</u></a>	Dr. Nehal Lakhani
<a href="#"><u>Selpercatinib in non-MTC, RET-mutated tumors: Efficacy in MEN-associated and other tumors.</u></a>	Dr. Nehal Lakhani
<a href="#"><u>Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).</u></a>	Dr. Nehal Lakhani
<a href="#"><u>Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.</u></a>	Dr. Nehal Lakhani



Session Name	START Principal Investigator
<a href="#"><u>An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).</u></a>	Dr. Nehal Lakhani
<a href="#"><u>A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.</u></a>	Dr. Nehal Lakhani
<a href="#"><u>A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.</u></a>	Dr. Nehal Lakhani
<a href="#"><u>IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.</u></a>	Dr. Nehal Lakhani
<a href="#"><u>First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.</u></a>	Dr. Nehal Lakhani
<a href="#"><u>Phase II dose optimization with EZH2/EZH1 inhibitor talmimetostat in patients (pts) with advanced solid tumors or hematologic malignancies.</u></a>	Dr. Nehal Lakhani



Session Name	START Principal Investigator
<a href="#"><u>Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).</u></a>	Dr. William B. McKean
<a href="#"><u>Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors.</u></a>	Dr. William B. McKean
<a href="#"><u>Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors.</u></a>	Dr. Justin A. Call
<a href="#"><u>Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).</u></a>	Dr. Justin A. Call
<a href="#"><u>Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors.</u></a>	Dr. Justin A. Call
<a href="#"><u>A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.</u></a>	Dr. Justin A. Call
<a href="#"><u>An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).</u></a>	Dr. Justin A. Call



Session Name	START Principal Investigator
<a href="#"><u>Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).</u></a>	Dr. Emiliano Calvo
<a href="#"><u>EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.</u></a>	Dr. Emiliano Calvo
<a href="#"><u>Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).</u></a>	Dr. Emiliano Calvo
<a href="#"><u>Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).</u></a>	Dr. Emiliano Calvo
<a href="#"><u>EVICTON study: ICT01, an anti-Butyrophilin 3A monoclonal antibody activating <math>\gamma\delta 2</math> T cells in combination with pembrolizumab in checkpoint inhibitor refractory melanoma.</u></a>	Dr. Emiliano Calvo
<a href="#"><u>Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02.</u></a>	Dr. Emiliano Calvo
<a href="#"><u>Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.</u></a>	Dr. Emiliano Calvo





Session Name	START Principal Investigator
<a href="#"><u>Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.</u></a>	Dr. Victor Moreno
<a href="#"><u>Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2-p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study.</u></a>	Dr. Victor Moreno
<a href="#"><u>Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin.</u></a>	Dr. Victor Moreno
<a href="#"><u>Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.</u></a>	Dr. Victor Moreno
<a href="#"><u>Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.</u></a>	Dr. Victor Moreno
<a href="#"><u>Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.</u></a>	Dr. Victor Moreno



Session Name	START Principal Investigator
<p><a href="#"><u>Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry.</u></a></p>	<p>Dr. Victor Moreno</p>
<p><a href="#"><u>A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), and to determine the recommended phase 2 dose (RP2D) of subcutaneous (SC) cetrelimab (CET) in patients (pts) with advanced solid malignancies.</u></a></p>	<p>Dr. Victor Moreno</p>
<p><a href="#"><u>EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.</u></a></p>	<p>Dr. Victor Moreno</p>
<p><a href="#"><u>CIn-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.</u></a></p>	<p>Dr. Victor Moreno</p>
<p><a href="#"><u>First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.</u></a></p>	<p>Dr. Victor Moreno</p>
<p><a href="#"><u>A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.</u></a></p>	<p>Dr. Victor Moreno</p>



Session Name	START Principal Investigator
<a href="#"><u>Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry.</u></a>	Dr. Daniel Morillo
<a href="#"><u>Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.</u></a>	Dr. Manuel Pedregal
<a href="#"><u>AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.</u></a>	Dr. Bernard Doger De Speville
<a href="#"><u>Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry.</u></a>	Dr. Bernard Doger De Speville
<a href="#"><u>Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.</u></a>	Dr. Bernard Doger De Speville
<a href="#"><u>Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.</u></a>	Dr. Bernard Doger De Speville



Session Name	START Principal Investigator
<a href="#"><u>A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.</u></a>	Dr. Maria de Miguel
<a href="#"><u>Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.</u></a>	Dr. Maria de Miguel
<a href="#"><u>Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).</u></a>	Dr. Maria de Miguel
<a href="#"><u>Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.</u></a>	Dr. Maria de Miguel
<a href="#"><u>Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.</u></a>	Dr. Maria de Miguel
<a href="#"><u>Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry.</u></a>	Dr. Tatiana Hernandez-Guerreo
<a href="#"><u>EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.</u></a>	Dr. Tatiana Hernandez-Guerreo